Asset profile
vidofludimus calcium
Unknown / undisclosed
Evidence outlook · program status
Discontinued (2022-11), after a negative readout
Vidofludimus calcium (IMU-838) is Immunic's oral DHODH inhibitor. The Phase 2 ulcerative colitis trial CALDOSE-1 (NCT03341962) is Terminated because the drug did not beat placebo in induction, so the open-label extension was closed early. This row is market-scoped to ulcerative colitis: the molecule itself remains in active Phase 3 multiple sclerosis trials (NCT05134441, NCT05201638, both Active, not recruiting, updated 2026-02-23). The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Competitive landscape
44 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 43 same-indication; 27 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Vidofludimus Calcium: this drug | Phase 3 | — | Dihydroorotate dehydrogenase (DHODH) | ||
| Teriflunomide HMR1726 | Approved | Small molecule | Dihydroorotate dehydrogenase (DHODH) | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | ||
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Cladribine (MAVENCLAD®) | Approved | Small molecule | Adenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytes | ||
| Copaxone | Approved | Peptide | Myelin basic protein-mimetic immunomodulation | ||
| Dimethyl Fumarate (Tecfidera) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Diroximel Fumarate (Vumerity) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| DRF | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Fampridine (Ampyra / Fampyra) | Approved | Small molecule | Potassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family) | ||
| Fingolimod (Gilenya) | Approved | Small molecule | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | ||
| Interferon Beta-1a (Avonex) | Approved | Biologic (subtype unspecified) | Type I Interferon receptor (IFNAR) | ||
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Interferon-Beta1 | Approved | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Mayzent | Approved | Small molecule | S1P receptor |
…and 29 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.